Jazz Pharma PLC (NASDAQ:JAZZ) Earnings Model
Models From Our Community
Contributor Model by: Frank DePinto
Last Update: November 20, 2016
View on Jazz: Bearish
Summary of Model Estimates: Updated Q32016 financials and lowered assumptions for 2017 revenue and EPS assumptions. According to commentary in the 10-K, Jazz is facing increasing threats from generic competition. The firm is also too reliant for my liking on sales of Xyrem, the primary drug facing generic competition. I also don't believe that Jazz is developing drugs in areas that are poised for tremendous patient growth or areas of unmet medical need. It seems like a majority of their clinical trial outlook is related to new indications for existing drugs in their portfolio. All in all, I don't necessarily have the most upbeat outlook for Jazz Pharmaceuticals for FY2017.
Click here to visit Frank's contributor page.
Gutenberg Modeling Guide
New to earnings modeling?
Our modeling guide demonstrates step-by-step how to create a financial model.